The Anti-diabetic Drug Gliquidone Modulates Lipopolysaccharide-Mediated Microglial Neuroinflammatory Responses by Inhibiting the NLRP3 Inflammasome

The sulfonylurea drug gliquidone is FDA approved for the treatment of type 2 diabetes. Binding of gliquidone to ATP-sensitive potassium channels (SUR1, Kir6 subunit) in pancreatic β-cells increases insulin release to regulate blood glucose levels. Diabetes has been associated with increased levels of neuroinflammation, and therefore the potential effects of gliquidone on micro- and astroglial neuroinflammatory responses in the brain are of interest. Here, we found that gliquidone suppressed LPS-mediated microgliosis, microglial hypertrophy, and proinflammatory cytokine COX-2 and IL-6 levels in wild-type mice, with smaller effects on astrogliosis. Importantly, gliquidone downregulated the LPS-induced microglial NLRP3 inflammasome and peripheral inflammation in wild-type mice. An investigation of the molecular mechanism of the effects of gliquidone on LPS-stimulated proinflammatory responses showed that in BV2 microglial cells, gliquidone significantly decreased LPS-induced proinflammatory cytokine levels and inhibited ERK/STAT3/NF-κB phosphorylation by altering NLRP3 inflammasome activation. In primary astrocytes, gliquidone selectively affected LPS-mediated proinflammatory cytokine expression and decreased STAT3/NF-κB signaling in an NLRP3-independent manner. These results indicate that gliquidone differentially modulates LPS-induced microglial and astroglial neuroinflammation in BV2 microglial cells, primary astrocytes, and a model of neuroinflammatory disease.


INTRODUCTION
Diabetes mellitus is a serious metabolic disorder characterized by elevated blood glucose levels (hyperglycemia) due to improper insulin function (Ramos- Rodriguez et al., 2014). Long-term hyperglycemia can impair macrovascular and microvascular function and cause brain atrophy, neuropathy, and neuroinflammation (Wrighten et al., 2009;Ramos-Rodriguez et al., 2014).
Moreover, type 2 diabetes and insulin resistance can lead to peripheral meta-inflammation and an overproduction of proinflammatory cytokines (Ferreira et al., 2014). Clusters of proteins that are differentially regulated in type 2 diabetes have also been linked to neuroinflammation and related neurodegenerative diseases, including Alzheimer's disease (AD) (Mittal et al., 2016). Clinical studies have shown that some classes of diabetes medications can rescue both glycemic control and inflammation-linked deficits, providing benefits for cognitive function and reducing dementia risk (Chatterjee and Mudher, 2018;Weinstein et al., 2019;Akimoto et al., 2020). However, the molecular mechanisms by which diabetes medications affect neuroinflammatory responses have not been fully elucidated.
Therapeutic interventions for type 2 diabetes include the class of drugs known as sulfonylureas, such as gliquidone and glibenclamide. These drugs bind the sulfonylurea receptor on the surface of pancreatic β-cells, which functions as a subunit of ATP-sensitive potassium (K-ATP) channels (Aquilante, 2010;Sola et al., 2015). Gliquidone inhibits K + efflux in the cell membrane, resulting in depolarization, activation of voltagegated calcium channels and calcium influx (de Wet and Proks, 2015). The resulting increase in calcium conductance leads to insulin expression and release (Yang and Berggren, 2006). Isotope tracing studies using [ 3 H]glibenclamide ([ 3 H]Grb) have demonstrated that glibenclamide crosses the blood-brain barrier (BBB) in wild-type mice. In addition, glibenclamide reaches the brain more easily after cerebral ischemic insult (Angel and Bidet, 1991;Ortega et al., 2012). As further evidence that sulfonylurea drugs can cross the BBB, gliquidone injection decreases the immobility time of mice in the forced swimming test (Galeotti et al., 1999), and gliquidone significantly decreases cromakalimevoked potassium efflux in slices of the rat substantia nigra (Schmid-Antomarchi et al., 1990). These observations suggest that the sulfonylurea family of type 2 diabetes drugs may provide additional potential therapeutic benefits by reducing insulinmediated neuroinflammation.
To address this gap, in this study we investigated whether gliquidone affects lipopolysaccharide (LPS)-stimulated microand astroglial neuroinflammatory responses. We found that gliquidone suppressed LPS-induced microglial activation and proinflammatory cytokine levels by altering NLRP3 inflammasome activation in wild-type mice, with smaller effects on astrogliosis. In BV2 microglial cells, gliquidone significantly suppressed the LPS-induced increase in proinflammatory cytokine levels by altering ERK/STAT3/NF-κB signaling. Importantly, gliquidone downregulated LPS-mediated neuroinflammatory responses in BV2 microglial cells by inhibiting NLRP3 inflammasome formation. In primary astrocytes, gliquidone reduced LPS-induced neuroinflammatory responses by regulating STAT3/NF-κB signaling but not NLRP3 inflammasome activation. Taken together, these data suggest that the anti-diabetic drug gliquidone may be a new therapeutic intervention for neuroinflammation-mediated neuropathy in the brain.

Ethics Statement
All experiments were approved by the institutional biosafety committee (IBC) and performed in accordance with approved animal protocols of the Korea Brain Research Institute (KBRI, approval no. IACUC-19-00042).

C57BL6/N Mice
Male C57BL6/N mice (wild-type; Hana Company, Busan, South Korea) were used in in vivo experiments. A pathogenfree facility with a 12 h light/dark cycle and a temperature of 22 • C was used to house all mice. Daily injections of gliquidone (10 or 20 mg/kg) or vehicle (5% DMSO) were administered intraperitoneally (i.p.) on 3 consecutive days. On the third day, 10 mg/kg LPS (i.p.) or PBS was injected. The mice were sacrificed 8 h after the last injection and fixed in 4% paraformaldehyde. Subsequently, mouse brain slices with a thickness of 30 µm were prepared using a Leica CM1850 cryostat (Leica Biosystems, Buffalo Grove, IL, United States).

Immunofluorescence Staining
Mouse brain slices were incubated in 10% normal goat serum (Vector Laboratories) at room temperature for 1 h, followed by immunostaining with rabbit or mouse anti-target antibody at 4 • C overnight. The sections were subsequently incubated with an Alexa Fluor 488-or 555-labeled goat IgG secondary antibody for 2 h at room temperature. Sections were mounted on glass slides were covered with a DAPI (Vector Laboratories)containing mounting solution, and images were obtained by fluorescence microscopy (DMi8, Leica Microsystems, Wetzlar, Germany) for analysis by Image J software (NIH). Detailed information on the primary and secondary antibodies used for IF and immunocytochemistry (ICC) is provided in Table 1.

Enzyme-Linked Immunosorbent Assay
Wild-type mice were injected daily with gliquidone (10 or 20 mg/kg, i.p.) or vehicle (5% DMSO + 10% PEG + 20% Tween80) for 3 days, followed by injection of LPS (10 mg/kg, i.p.) or PBS 30 min after the last injection on day 3. Eight hours later, blood was sampled and centrifuged at 2,000 rpm for 20 min, and the supernatant (serum) collected and stored at −80 • C until analysis. Peripheral IL-1β, IL-6, and TNF-α levels were measured using the appropriate ELISA kit ; Invitrogen, Waltham, MA, United States) as described by the manufacturer.

Mice Brain-Derived Primary Astrocyte Culture
Primary astrocytes were prepared from postnatal day 1 (P1) C57BL6/N mice as previously described (Ryu et al., 2019). Briefly, whole brains were dissected and minced through 70 µm mesh, and the mixed cells were grown in low-glucose DMEM (1,000 mg/l glucose) supplemented with 10% FBS, 100 unit/ml penicillin, and 100 µg/ml streptomycin for 2 weeks. On day 14, primary microglial cells were detached by shaking at 250 rpm at room temperature overnight, followed by dissociation of primary astrocytes using trypsin-EDTA. After 3 rounds of washing and centrifugation for 10 min at 2,000 rpm, the pellet containing primary astrocytes was used for experiments. The cells were seeded at 7.0 × 10 5 cells/well in 12-well plates for q-PCR and 2.5 × 10 5 cells/well for ICC. After 2 days, the primary astrocytes were fixed in 4% paraformaldehyde at room temperature for 10 min and immunostained with an antibody against GFAP (a marker of astrocytes) at 4 • C overnight. Next, the cells were washed thrice with PBS, and secondary antibodies were added for 1 h. Finally, the cells were washed with PBS, incubated with DAPI, and mounted. Images were acquired by fluorescence microscopy (DMi8, Leica Microsystems, Wetzlar, Germany), and primary astrocyte purity was calculated as follows: [Astrocyte purity (%) = (GFAP-and DAPI-positive cells/DAPI-positive cells) × 100].

Reverse Transcription-Polymerase Chain Reaction
Reverse transcription-polymerase chain reaction was performed to assess the effects of gliquidone on LPS-evoked microglial and astroglial inflammatory cytokine levels. First, total RNA was isolated from BV2 microglial cells or primary astrocytes using QIAzol Lysis Reagent (Qiagen,Cat No. 79306) and reverse transcribed into cDNA. The cDNA was subsequently used as the template in RT-PCR using Prime Taq Premix (GeNet Bio) as previously described with the primers shown in Table 2. The amplicons were separated by electrophoresis on a 1.5% agarose gel containing EcoDye (1:5000, Biofact, Daejeon, South Korea), and images were analyzed using the software Fusion Capt Advance (Vilber Lourmat, Eberhardzell, Germany).

Real-Time PCR (q-PCR)
The effects of gliquidone on LPS-mediated microglial and astroglial NLRP3 inflammasome activation and subsequent proinflammatory cytokine production were assessed in BV2 microglial cells and mouse primary astrocytes.     value for gapdh, and the fold change relative to the vehicle-treated control was quantified. Used primers are shown in Table 3.

Western Blotting
To determine the effects of gliquidone on LPS-induced ERK signaling, western blotting was conducted. BV2 cells or primary astrocytes were lysed using lysis buffer (ProPrep, iNtRON Biotechnology, Inc., Seongnam, South Korea), followed by centrifugation at 12,000 rpm for 15 min. After quantifying the protein concentration in the supernatant, 15 µg of protein sample was separated by 8% SDS gel electrophoresis. The proteins in the gel were subsequently transferred to a polyvinylidene difluoride (PVDF) membrane. After blocking with 5% skim milk or 5% BSA at room temperature for 1 h, the membrane was incubated with anti-p-ERK (1:1000, Cell Signaling), anti-ERK (1:1000, Cell Signaling), or β-actin (1:1000, Santa Cruz Biotechnology) at 4 • C. Finally, HRPconjugated goat anti-mouse IgG or HRP-conjugated goat antirabbit IgG (both 1:1000, Enzo Life Sciences, Farmingdale, NY, United States) was added to the membrane and incubated for 1 h, and detection was performed using ECL Reagent (GE Healthcare, Chicago, IL, United States). Fusion Capt Advance software was used for image acquisition and analysis (Vilber Lourmat).

Immunocytochemistry
BV2 microglial cells and primary astrocytes were fixed in 4% paraformaldehyde for 10 min, washed thrice with PBS, and incubated overnight with anti-target antibody in GDB buffer as described previously (Nam et al., 2018).
After washing with PBS, the cells were incubated for 1 h with an Alexa Fluor 488-or 555-conjugated antibody at room temperature. Finally, images of cells mounted in DAPI (Vector Laboratories, CA, United States) were captured using a fluorescence microscope (DMi8, Leica Microsystems, Wetzlar, Germany) and analyzed using ImageJ software.

Statistical Analyses
GraphPad Prism 7 software (GraphPad Software, San Diego, CA, United States) was used for data analyses. Comparisons between two groups were performed using the unpaired two-tailed T-test with Welch's correction; one-way ANOVA was employed for multiple comparisons (except for hippocampal NLRP3 IF). Tukey's test or the Newman-Keuls multiple comparisons test was used for multiple comparisons with significance set at p < 0.05. Means ± SD are presented ( * p < 0.05, * * p < 0.01, * * * p < 0.001).

Gliquidone Decreases Lipopolysaccharide-Stimulated Microgliosis and Hypertrophy in a Model of Neuroinflammatory Disease
The anti-diabetic drug gliquidone was recently shown to promote a beneficial microglial phenotype via the Kir6containing ATP-dependent potassium channel in a mouse model of Parkinson's disease (PD) (Du et al., 2018). However, the effects of gliquidone on LPS-induced proinflammatory responses are unknown. Therefore, we investigated whether gliquidone modulates LPS-mediated microglial activity by injecting wildtype mice daily with gliquidone (10 or 20 mg/kg, i.p.) or vehicle for 3 days; after the final administration of gliquidone, LPS (10 mg/kg, i.p.) or PBS was injected. Eight hours after LPS or PBS injection, IF staining of brain slices was performed with an anti-Iba-1 antibody, and Iba-1 intensity, Iba-1-positive cells, and Iba-1-labeled area were analyzed in the cortex and hippocampus (Figures 1A-E). Treatment with 20 mg/kg gliquidone significantly decreased the LPS-induced increases in Iba-1 immunoreactivity, Iba-1-positive cells, and Iba-1-labeled area in the cortex and hippocampal CA1 and CA3 regions (Figures 1A-E). By contrast, administration of 10 mg/kg gliquidone significantly reduced the LPS-induced increases in Iba-1 intensity, Iba-1-positive cells, and Iba-1-labeled area only in the hippocampal CA3 region (Figures 1C-E).
These results indicated that a gliquidone dose of 20 mg/kg more effectively downregulates LPS-mediated microgliosis and changes in microglial kinetics and morphology in the wildtype mouse brain.
To determine if gliquidone alters LPS-evoked astrocyte activation in vivo, we treated wild-type mice according to same paradigm described above and performed IF staining of brain slices with an anti-GFAP antibody. GFAP intensity, GFAP-positive cells, and GFAP-labeled area were measured (Figures 2A-E). At doses of 10 and 20 mg/kg, gliquidone significantly reduced the LPS-induced increases in GFAP immunointensity and GFAP-positive cells in the cortex but not the hippocampus (Figures 2C-E). In addition, administration of 10 or 20 mg/kg gliquidone did not alter GFAP-labeled area in the cortex and hippocampus ( Figure 2E). These data indicate that gliquidone modulates LPS-stimulated astrocyte activation in the mouse brain, albeit less effectively than microglial activation.

Gliquidone Eliminates
Lipopolysaccharide-Induced Increases in COX-2 and IL-6 Proinflammatory Cytokine Levels in Wild-Type Mice Since gliquidone downregulated LPS-induced micro-and astrogliosis in wild-type mice, we next investigated whether gliquidone modulates LPS-stimulated proinflammatory cytokine levels in vivo. Wild-type mice were treated as described above, and brain slices were subjected to IF staining with anti-COX-2 or anti-IL-6 antibodies. Treatment with 20 mg/kg gliquidone significantly diminished LPS-stimulated levels of COX-2 in the cortex and hippocampal CA3 region but not the hippocampal CA1 and DG regions (Figures 3A-C). At a dose of 10 mg/kg, gliquidone significantly decreased the LPS-evoked increase in COX-2 levels in the cortex and hippocampal CA3 region (Figures 3A-C). Moreover, injection of 10 or 20 mg/kg gliquidone following LPS administration markedly suppressed IL-6 levels in the cortex and hippocampus in wild-type mice, and the effects of 10 mg/kg gliquidone were significantly greater than those of 20 mg/kg gliquidone (Figures 4A-C). These findings suggest that gliquidone suppresses LPS-stimulated COX-2 and IL-6 levels in a model of neuroinflammatory disease.

Gliquidone Inhibits Lipopolysaccharide-Stimulated NLRP3 Inflammasome Activation in Wild-Type Mice
The induction of proinflammatory cytokines by LPS is closely linked to microglia-and/or astrocyte-associated inflammation as well as inflammasome formation (Su et al., 2021;Zhao et al., 2021). Thus, we examined whether gliquidone affects LPS-induced NLRP3 inflammasome activation in vivo. Wild-type mice were treated as described above, and IF staining of brain slices was conducted with an anti-NLRP3 antibody. Injection of 10 mg/kg gliquidone significantly decreased LPS-induced NLRP3 activation in the cortex and hippocampus (Figures 5A-C), whereas 20 mg/kg gliquidone effectively diminished LPS-induced NLRP3 levels in the cortex but not the hippocampus (Figures 5A-C). These data indicate that gliquidone decreases LPS-stimulated NLRP3 inflammasome formation in the mouse brain.

Gliquidone Downregulates Lipopolysaccharide-Induced Peripheral Proinflammatory Cytokine Levels in Wild-Type Mice
To investigate whether gliquidone alters peripheral proinflammatory cytokine levels in vivo, wild-type mice FIGURE 1 | Gliquidone decreases LPS-stimulated microgliosis and hypertrophy in the cortex and hippocampus in C57BL6/N mice. The in vivo experimental procedure for gliquidone and LPS injection is shown at the top of the figure. (A,B) Immunofluorescence staining of Iba-1 expression in brain slices from mice treated as described in the experimental procedure. (C-E) Quantification of the results in (A,B) (n = 10-18 brain slices from 4 mice/group). *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar = 100 µM.
were treated as described above, followed by measurement of proinflammatory cytokine levels in peripheral blood by ELISA. Treatment of wild-type mice with 10 or 20 mg/kg gliquidone significantly abolished the LPS-induced increases in serum IL-1β and IL-6 levels but not TNF-α (Supplementary Figures 1A-C).
These data indicate that gliquidone selectively alters peripheral proinflammatory cytokine levels in LPS-treated wild-type mice.

Post-and Pretreatment of BV2 Microglial Cells With Gliquidone Abolishes Lipopolysaccharide-Induced Proinflammatory Cytokine mRNA Levels
Since gliquidone regulates micro/astroglial activation, proinflammatory cytokine levels, and NLRP3 inflammasome activation in LPS-treated wild-type mice, we next verified the effects of gliquidone on LPS-mediated proinflammatory cytokine levels in vitro. We first assessed gliquidone cytotoxicity and induction of mitochondrial arrest using CCK or MTT assays in BV2 microglial cells. No cytotoxicity was observed in BV2 microglial cells after treatment with up to 50 µM gliquidone for 6 h (Figures 6A,B). In BV2 microglial cells treated for 24 h, gliquidone had no cytotoxicity up to 25 µM, but 50 µM gliquidone significantly diminished cell viability ( Figure 6C). Based on these data, a gliquidone concentration of 5 µM, 10-fold lower than the concentration producing mitochondrial dysfunction, was used in subsequent experiments.
Gliquidone is a ligand of SUR1, which is part of the Kir6 channel (Wu et al., 2018), and thus we assessed the effects of gliquidone on SUR1 mRNA levels as well as proinflammatory cytokine levels by q-PCR. Treatment of BV2 microglial cells with gliquidone alone for 6 or 24 h did not alter SUR1 mRNA levels ( Figure 6D). In addition, gliquidone alone reduced COX-2 mRNA levels but did not affect IL-1β, iNOS, and IL-6 mRNA levels in BV2 microglial cells (Figure 6E). These results indicate that 5 µM gliquidone itself selectively affects mRNA levels of the proinflammatory cytokine COX-2.
We then examined the effects of gliquidone on LPS-stimulated microglial SUR1 and proinflammatory cytokine mRNA levels in BV2 microglial cells. Cells were pretreated for 30 min with 200 ng/ml LPS or PBS and treated for 5.5 or 23.5 h with 5 µM gliquidone or vehicle (1% DMSO). Treatment with 5 µM gliquidone for 23.5 h but not 5.5 h significantly abolished the LPS-induced increase in SUR1 mRNA levels in BV2 microglial cells (Figure 6F). In addition, RT-PCR analysis showed that gliquidone post-treatment significantly reduced the LPS-induced increases in IL-1β, IL-6, iNOS, and COX-2 mRNA levels (Figures 6G,H). Confirming these results, q-PCR showed significant reductions in LPS-mediated IL-1β, IL-6, and COX-2 mRNA levels, with a trend toward decreased iNOS mRNA levels ( Figure 6I). Moreover, we found that pretreatment with 5 µM gliquidone for 30 min significantly reduced the increases in IL-1β, IL-6, iNOS, and COX-2 mRNA levels in BV2 microglial cells induced by treatment with 200 ng/ml LPS for 5.5 h ( Supplementary Figures 2A-C). Taken together, these results show that post-and pretreatment with gliquidone modulates LPS-induced microglial proinflammatory responses in vitro.
To examine whether gliquidone affects LPS-stimulated microglial ERK signaling, BV2 microglial cells treated with 200 ng/ml LPS or PBS for 45 min were post-treated with 5 µM gliquidone or vehicle (1% DMSO) for 45 min. Subsequently, Western blotting was conducted with anti-p-ERK, anti-ERK, and anti-β-actin antibodies. Gliquidone significantly decreased the LPS-induced increase in p-ERK levels but did not alter total ERK or β-actin levels (Figures 7C,D).
To assess the effects of gliquidone itself on nuclear STAT3 or NF-κB phosphorylation, BV2 microglial cells were sequentially treated with PBS for 30 min and 5 µM gliquidone or vehicle (1% DMSO) for 5.5 h, and ICC was performed with anti-p-STAT3 s727 or anti-p-NF-κB antibodies. We found that gliquidone alone did not alter nuclear p-STAT3 and p-NF-κB levels in BV2 microglial cells (Figures 7E-H).
We then tested whether gliquidone alters LPS-mediated nuclear STAT3/NF-κB phosphorylation, BV2 microglial cells were sequentially treated with 200 ng/ml LPS or PBS for 30 min and 5 µM gliquidone or vehicle (1% DMSO) for 5.5 h. ICC assay demonstrated that gliquidone significantly FIGURE 5 | Gliquidone eliminates the LPS-mediated increase in NLRP3 inflammasome levels in the brain in C57BL6/N mice. (A,B) Immunofluorescence staining of NLRP3 in brain slices from mice treated as shown at the top of the figure. (C) Quantification of the results in (A,B) (n = 7-19 brain slices from 4 mice/group). *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar = 100 µM.
reduced the LPS-mediated increases in nuclear STAT3 and NF-κB phosphorylation in BV2 microglial cells (Figures 7I-L).
These results indicate that gliquidone modulates downstream ERK/STAT3 or NF-κB signaling regulated by TLR4 and ATPsensitive K + channels in microglial cells in response to neuroinflammation.
We then investigated the effects of gliquidone on LPSmediated microglial NLRP3 inflammasome activation. After treatment for 30 min with 200 ng/ml LPS or PBS, BV2 microglial cells were treated with 5 µM gliquidone or vehicle (1% DMSO) for 5.5 h or 23.5 h, and NLRP3/pro-IL-1β mRNA levels were detected by q-PCR. Post-treatment with gliquidone for 5.5 h significantly reduced LPS-enhanced pro-IL-1β mRNA levels, and a trend toward decreased NLRP3 mRNA levels was observed (Figures 8D,E). In addition, LPS-induced NLRP3 mRNA levels were markedly decreased by post-treatment with gliquidone for 23.5 h (Figure 8F). ICC analysis showed that gliquidone significantly downregulated LPS-induced microglial NLRP3 protein levels (Figures 8G,H). These data imply that gliquidone regulates the LPS-induced neuroinflammatory  responses by decreasing NLRP3 inflammasome formation in BV2 microglial cells.

Gliquidone Reduces Lipopolysaccharide-Evoked IL-1β and IL-6 mRNA Levels in Primary Astrocytes
Since gliquidone downregulates LPS-mediated microglial neuroinflammatory responses in BV2 microglial cells, we next examined the effects of gliquidone on LPS-induced astrocytic neuroinflammatory responses. Mouse primary astrocytes were treated with 200 ng/ml LPS or PBS for 0.5 h and post-treated with 5 µM gliquidone or vehicle (1% DMSO) for 5.5 or 23.5 h. q-PCR analysis showed that gliquidone post-treatment for 5.5 or 23.5 h did not alter SUR1 mRNA levels (Figures 9A,B). In addition, gliquidone post-treatment significantly decreased LPS-stimulated IL-1β and IL-6 mRNA levels but did not alter iNOS and COX-2 mRNA levels (Figures 9C-F). These results suggest that gliquidone modulates proinflammatory cytokines less effectively in astrocytes than in microglia.

Gliquidone Downregulates Lipopolysaccharide-Stimulated Nuclear STAT3 and NF-κB Phosphorylation in Primary Astrocytes
Given the significant reduction of downstream ERK signaling in BV2 microglial cells treated with gliquidone (Figure 7), we then investigated the effects of gliquidone on LPS-mediated astrocytic ERK signaling. Initially, we evaluated the purity of the primary astrocytes culture by measuring the GFAP/DAPI ratio, indicating an astrocyte purity of greater than 80% (Supplementary Figures 3A,B). Subsequently, mouse primary astrocytes were treated with 200 ng/ml LPS or PBS for 0.5 h followed by 5 µM gliquidone or vehicle (1% DMSO) for 5.5 h, and ICC was performed with an anti-p-ERK antibody. Gliquidone treatment did not affect LPS-evoked ERK phosphorylation in primary astrocytes (Supplementary  Figures 3C,D).
Next, we examined the effects of gliquidone on LPS-induced astrocytic STAT3 or NF-κB phosphorylation in the nucleus. Again, we first confirmed that our primary astrocytes had a purity of greater than 80% (Figures 10A,B). Subsequent ICC analysis of cells treated as described above with anti-CD11b and anti-p-STAT3 S727 or anti-CD11b and p-NF-κB S536 antibodies indicated that gliquidone significantly reduced the LPS-stimulated increases in nuclear STAT3 and NF-κB phosphorylation in primary astrocytes (Figures 10C-F).
These results indicate that gliquidone modulates LPS-mediated astrocytic STAT3 or NF-κB signaling in a p-ERK-independent manner in response to neuroinflammation.

Gliquidone Does Not Modulate Lipopolysaccharide-Induced NLRP3 Inflammasome Activation in Primary Astrocytes
Since gliquidone downregulated LPS-evoked proinflammatory cytokine levels and nuclear STAT3 and NF-κB phosphorylation in primary astrocytes, we further examined the effects of gliquidone on LPS-induced astrocytic NLRP3 inflammasome activation. Mouse primary astrocytes were treated with 200 ng/ml LPS or PBS for 0.5 h and post-treated with 5 µM gliquidone or vehicle (1% DMSO) for 5.5 h or 23.5 h, and NLRP3 and pro-IL-1β were detected by q-PCR or ICC. Gliquidone post-treatment for 5.5 h significantly diminished the LPS-induced increase in pro-IL-1β mRNA levels, whereas no changes in NLRP3 mRNA and protein levels were observed after gliquidone post-treatment for 5.5 or 23.5 h (Supplementary Figures 4A-D). These results indicate that gliquidone regulates LPS-mediated astrocytic proinflammatory cytokine levels by inhibiting STAT3/NF-κB signaling but does not modulate ERK signaling and NLRP3 inflammasome activation in primary astrocytes in vitro.

DISCUSSION
In this study, we demonstrated that gliquidone, a sulfonylurea drug that selectively binds sulfonylurea receptor subunit 1 (SUR1), significantly reduced LPS-induced microglial activation and COX-2 and IL-6 proinflammatory cytokine levels by inhibiting NLRP3 inflammasome activation in a model of neuroinflammatory disease, with smaller effects on astrogliosis. In LPS-treated BV2 microglial cells, gliquidone diminished LPS-induced microglial proinflammatory cytokine levels and downstream ERK/STAT3/NF-κB phosphorylation by suppressing NLRP3 inflammasome formation. By contrast, in primary astrocytes, gliquidone selectively abolished LPSstimulated astrocytic proinflammatory cytokine levels by diminishing STAT3/NF-κB activation via NLRP3-independent mechanisms. The ability of gliquidone to alter LPS-mediated micro-and astroglial neuroinflammation in vitro and in vivo suggests that this drug could be useful for the prevention and/or treatment of neuroinflammation-associated diseases.
K-ATP channels regulate microglial and astroglia activation by controlling membrane electrical changes and mitochondrial ATP metabolism . In cultured microglia derived from wild-type mice, LPS and interferon-γ (IFN-γ) cotreatment upregulates Kir 6.1 and Kir 6.2 (Virgili et al., 2011), and the K-ATP channel blocker glimepiride significantly reduces the expression of CD14 in BV2 microglial cells and primary microglia (Ingham et al., 2014). In addition, glibenclamide, a K-ATP channel blocker, alleviates neuroinflammation by inhibiting NLRP3 inflammasome activation in BV2 microglial cells and significantly reduces morphine-mediated Iba-1 fluorescence intensity in the spinal cord in mice (Qu et al., 2017). Moreover, K-ATP channels in astrocytes have been closely linked to neurodegeneration via mitophagy in a mouse model of PD, which increases NLRP3 inflammasome formation (Du et al., 2018). In the present study, we found that exposure to the K-ATP channel FIGURE 11 | Gliquidone affects LPS-stimulated neuroinflammatory responses in vitro and in vivo. In BV2 microglial cells and wild-type mice, gliquidone reduces LPS-stimulated microglial proinflammatory cytokine expression by modulating ERK-associated STAT3/NF-κB signaling in an NLRP3-dependent manner. In primary astrocytes, gliquidone selectively downregulates LPS-induced astrocytic proinflammatory cytokine expression by decreasing STAT3/NF-κB phosphorylation via an NLRP3-independent pathway. Accordingly, gliquidone may have therapeutic potential for neuroinflammation-related neurodegenerative diseases.
antagonist gliquidone significantly decreased LPS-mediated microglial activation and hypertrophy in the brains of wild-type mice (Figure 1). In addition, gliquidone significantly decreased LPS-mediated astrocyte activation and the number of GFAPpositive cells in the cortex but not the hippocampus (Figure 2). Taken together with the literature, our findings suggest that gliquidone specifically modulates microglial activation rather than astrogliosis by regulating K-ATP channel signaling in this LPS-induced model of neuroinflammatory disease.
K-ATP channel blockers influence proinflammatory cytokine mRNA and/or protein levels and release (Nakamura et al., 2015;Qu et al., 2017;Du et al., 2019). For example, glibenclamide significantly suppresses LPS-induced plasma IL-6 and TNFα levels in ex vivo endotoxemia mice (Schmid et al., 2011). Daily administration of another sulfonylurea K-ATP channel blocker, gliclazide, significantly decreases serum TNF-α levels in albino LACA mice (Mourya et al., 2018). In the present study, gliquidone significantly suppressed LPS-induced COX-2 and IL-6 proinflammatory cytokine levels and peripheral inflammation in wild-type mice (Figures 3, 4 and Supplementary Figure 1). Moreover, gliquidone significantly downregulated LPS-mediated NLRP3 levels in wild-type mice (Figure 5). These data indicate that gliquidone and other K-ATP channel inhibitors can modulate proinflammatory cytokine expression as well as peripheral inflammation by altering NLRP3 inflammasome formation in vivo.
An important finding of this study is that gliquidone treatment significantly reduced LPS-mediated Iba-1, COX-2, IL-6, and NLRP3 levels in the cortex and/or hippocampal CA1/CA3 regions in wild-type mice but did not alter LPS-stimulated Iba-1 and COX-2 levels in the DG region (Figures 1, 3). However, this raises the question as to how does gliquidone differentially modulate the induction of Iba-1, COX-2, IL-6, and NLRP3 by LPS according to brain region? It is possible that the receptor subunit (i.e., SUR1 or Kir 6) and/or K-ATP channel targeted by gliquidone is differentially expressed in a brain region-specific manner (cortex, hippocampus CA1 vs. DG regions), resulting in differences in the effects of gliquidone on LPS-induced Iba-1, COX-2, IL-6, and NLRP3 levels between the cortex and hippocampus in wild-type mice. Another possibility is that a 3day duration of daily injections was not sufficient to influence LPS-stimulated Iba-1, COX-2, IL-6, and NLRP3 levels in the hippocampus (CA1 vs. DG region). Future work, will need to examine whether a differential expression of the target receptor subunit (SUR1 and Kir6) and/or K-ATP channel exists between the cortex and hippocampal CA1 vs. DG region and if this alters LPS-induced proinflammatory responses in the presence and absence of gliquidone. Furthermore, the effect of increasing the duration of gliquidone treatment (i.e., daily for 7 or 14 days) upon LPS-evoked neuroinflammation in the cortex and hippocampus should be examined and compared with 3 days injection protocol.
K-ATP channel blockers have been previously shown to modulate proinflammatory cytokine expression in vitro. For instance, the sulfonylurea K-ATP channel blocker glimepiride significantly reduced the LPS-induced increase in TNF-α expression in RAW 264 macrophage cells (Ingham et al., 2014). In BV2 microglial cells, glibenclamide significantly suppressed morphine-and LPS-induced proinflammatory cytokine levels (Qu et al., 2017;Xu et al., 2017). Gliquidone is a secondgeneration K-ATP blocker with few side effects, but its ability to modulate LPS-induced neuroinflammatory responses and its mechanism of action have not been investigated. Here, we found that either pre-or post-treatment with gliquidone significantly reduced LPS-induced proinflammatory cytokine expression in BV2 microglial cells, which express the K-ATP channel subunits Kir 6.1 and Kir 6.2 Du et al., 2018) (Figure 6 and Supplementary Figure 2). In primary astrocytes, gliquidone significantly diminished LPSinduced proinflammatory cytokine levels (Figure 9), suggesting that gliquidone modulates the target receptor itself and that blockade of K-ATPs is critical for proinflammatory cytokine production in microglia and astrocytes. In future work, we will perform epigenetic knockdown or inhibit individual K-ATP channel subunits (i.e., SUR1, SUR2B, Kir 6.1, Kir 6.2) to examine whether gliquidone alters LPS-mediated proinflammatory cytokine release by regulating SUR1 specifically or all four K-ATP subunits. Overall, our findings suggest that K-ATP channel modulation by gliquidone reduces LPS-induced proinflammatory cytokine release from glial cells.
Lipopolysaccharide binds TLR4 to stimulate TLR4-linked proinflammatory cytokine production and transcription factor activation in microglia and astrocytes (Park and Lee, 2013;Molteni et al., 2016). Under normal conditions, K-ATP channels regulate Ca 2+ influx, and increased Ca 2+ conductance activates TLR4-associated MAPK signaling in microglia (Katz et al., 2006;Sharma and Ping, 2014). Indeed, several studies have demonstrated that TLR4-and K-ATP-linked MAPK/ERK signaling modulates proinflammatory cytokine expression (Xiao et al., 2002;Lin and Chai, 2008;Cargnello and Roux, 2011;Plociennikowska et al., 2015). For example, the first-generation K-ATP channel antagonist tolbutamide significantly inhibits ERK phosphorylation in U87 glioma cells, and this decrease is rescued by the K-ATP channel agonist diazoxide (Huang et al., 2009). In BV2 microglial cells, the K-ATP channel antagonist and SUR1 agonist glibenclamide significantly reduces LPS-induced MAPK signaling (e.g., p-ERK, p-JNK, and p-P38) in a dosedependent manner (Xu et al., 2017). Here, we found that the anti-diabetic drug and second-generation K-ATP channel blocker gliquidone significantly reduced LPS-stimulated p-ERK levels in BV2 microglial cells but not in primary astrocytes (Figure 7 and Supplementary Figure 3), indicating that gliquidone affects TLR4-and K-ATP-associated ERK signaling in microglia. However, it is possible that gliquidone inhibits other MAPK signaling pathways to modulate LPS-induced proinflammatory responses; future experiments will address this possibility by using specific inhibitors and/or regulating gene expression levels (e.g., siRNA).
Given the effects of gliquidone on LPS-linked ERK phosphorylation in microglia, we investigated whether gliquidone modulates the transcription factor STAT3 and NF-κB, a downstream molecule that is crucial for promoting proinflammatory cytokine expression (Nam et al., 2018;Ryu et al., 2019). Recent studies have demonstrated links of K-ATP channels with STAT3 and NF-κB in the response to inflammation in the central nervous system (CNS) and peripheral nervous system (PNS). For instance, glibenclamide abolishes K-ATP channel opening-induced increases in rat hepatic p-STAT3 levels (Fouad et al., 2020). In human cerebrospinal fluid and cardiomyocytes, the K-ATP channel opener diazoxide and the mitochondrial K-ATP channel agonist rapamycin significantly increase STAT3 phosphorylation (Kishore et al., 2011;Das et al., 2012). Furthermore, morphine-induced impairment of the ATP/ADP ratio stimulates K-ATP channel-associated NF-κB activation by inducing NLRP3 inflammasome formation in microglia (Qu et al., 2017). In the present study, gliquidone significantly reduced LPS-mediated nuclear p-STAT3 and p-NF-κB levels in BV2 microglial cells and primary astrocytes (Figures 7, 10). Therefore, our findings and previous work suggest that gliquidone suppresses LPS-evoked STAT3/NF-κB activation by inhibiting K-ATP channels in microglia and primary astrocytes. It is possible that gliquidone affects LPSmediated proinflammatory cytokine production in microglia and/or astrocytes by inhibiting another transcription factor, such as NFATc-1 (nuclear factor of activated T-cells, cytoplasmic 1), which is known to be involved in TLR4-mediated downstream signaling. Thus, future studies will examine whether gliquidone affects other LPS-associated MAPK signaling pathways and transcription factors linked to K-ATP channels.
Excessive activation of the NLRP3 inflammasome is a key contributor to pathogenesis in various neuroinflammatory responses. In addition, associations of NLRP3 with intracellular K efflux/concentration in microglia and astrocytes have recently been reported. For example, numerous NLRP3 inflammasome activators [i.e., danger-associated molecular patterns (DAMPs) such as silica and uric acid crystals and pathogen-associated molecular patterns (PAMPs) such as LPS and morphine] are known to induce potassium efflux (Qu et al., 2017;Yang et al., 2019). The K-ATP channel agonist LLME (lysosomotropic agent Leu-Leu-O-methyl ester) significantly increases intracellular potassium efflux in C57BL/6 mice and Nlrp3 −/− mice, which induces NLRP3 inflammasome activation independent of calcium signaling (Katsnelson et al., 2015). In addition, K efflux and NLRP3 inflammasome activation are significantly increased in LLME-treated bone marrow-derived dendritic cells, suggesting that NLRP3 is closely linked to K-ATP channel activation (Katsnelson et al., 2016). Reducing the intracellular K + concentration is sufficient to activate NLRP3 inflammasome formation in nlrp3 −/− macrophages (Munoz-Planillo et al., 2013). Interestingly, the classic K-ATP channel blocker glibenclamide reduces morphine-induced neuroinflammation by inhibiting NLRP3 inflammasome activation in CD-1 mice (Qu et al., 2017). Consistent with these observations, we found that the second-generation K-ATP channel blocker gliquidone significantly inhibited LPS-mediated NLRP3 inflammasome activation in wild-type mice and BV2 microglial cells but not primary astrocytes (Figures 5, 8 and  Supplementary Figure 4). These data indicate that gliquidone differentially regulates LPS-mediated NLRP3 inflammasome activation to alter neuroinflammatory responses in microglia and astrocytes. The underlying mechanism by which gliquidone influences signaling factors involved in NLRP3 inflammasome formation requires further investigation in vivo and in vitro.

CONCLUSION
In summary, gliquidone downregulates LPS-stimulated increases in microglial morphology and activation as well as proinflammatory cytokine IL-6 and COX-2 levels by decreasing NLRP3 inflammasome formation in wild-type mice. Compared with its effects on microglia, gliquidone has smaller effects on astrogliosis and astroglial hypertrophy in LPS-treated wild-type mice. In BV2 microglial cells, gliquidone suppresses LPS-induced proinflammatory cytokine levels by modulating ERK/STAT3/NF-κB phosphorylation through the inhibition of NLRP3 inflammasome activation. In primary astrocytes, gliquidone selectively affects LPS-mediated proinflammatory cytokine levels and reduces STAT3/NK-kB phosphorylation in an NLRP3-independent manner (Figure 11). These results suggest that gliquidone has anti-inflammatory effects by modulating LPS-induced micro-and astroglial neuroinflammation and could be a novel therapy for neuroinflammation-related neurodegenerative diseases.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.